Klaria Pharma Holding AB (publ.) (KLAR.ST)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Scott Boyer | CEO & Director | 1.91M | -- | 1962 |
Mr. Hans Richter | Chief Financial Officer | -- | -- | 1949 |
Mr. Marc Willuhn Ph.D. | Head of Chemistry, Manufacturing & Control | -- | -- | 1969 |
Dr. Hans Olivecrona M.D., Ph.D. | Chief Medical Officer | -- | -- | 1958 |
Klaria Pharma Holding AB (publ.)
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 4
Description
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, as well as opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. Further, the company engages in the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available